Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Good morning, everybody, and thanks for joining day two of the JMP Life Science Conference. My name is John Walden. I'm pleased to have the team from Madrigal Pharmaceuticals joining us Rebecca Taub, CMO; CEO, Paul Friedman; and Chief Commercial Officer, Remy Sukhija. Thanks for joining us today, guys. I think everybody is familiar with the Madrigal story by now and the unmet need in NASH. But maybe to start, can we talk about the master of NASH data and the key learnings and then what that means moving forward for you guys?
Yeah. So as you know, we announced data the December of 42, and we have an update in January of 23 where we achieve both liver biopsy primary endpoints of the study, which was it's a 54-month study in overall, but there was a 52-week serial liver biopsy endpoint and about 1,000 patients. And we showed that resmetirom had both daily doses, 80 and 100 milligrams achieved the primary endpoints which
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
